Platelet activation by apoB100 76 Summary Low Density Lipoprotein (LDL) increases the sensitivity of human platelets for agonists by activating p38 MAPK . Antibody 4G3 disturbs apoB100 binding to the classical apoB/ E receptor and inhibits LDL-induced p38 MAPK activation, whereas an antibody against a distal domain on apoB100 has no effect. Peptide RLTRKRGLKLA mimics the binding domain of apoB100 called the B-site and activates platelet p38 MAPK . Activation by B-site peptide is dose-dependent, transient and followed by desensitization, in accordance with receptor-mediated signalling. A scrambled peptide and a partially homologous peptide RKLRKRLLRDA mimicking the apoB/E receptor binding site of apoE in High Density Lipoprotein (HDL) also activate p38 MAPK albeit 40% weaker, but an uncharged peptide lacks p38 MAPK activating capacity. LDL and B-site peptide bind to the same binding sites and initiate similar signaling to p38 MAPK and cytosolic phospholipase A 2 . Thus, LDL and to a lesser extent HDL activate platelets via specific domains in the protein moiety that recognize receptors of the LDL receptor family.
Chapter 4
Platelet activation by the apoB/E receptor-binding domain of LDL
Summary
Low Density Lipoprotein (LDL) increases the sensitivity of human platelets for agonists by activating p38
MAPK
. Antibody 4G3 disturbs apoB100 binding to the classical apoB/ E receptor and inhibits LDL-induced p38 MAPK activation, whereas an antibody against a distal domain on apoB100 has no effect. Peptide RLTRKRGLKLA mimics the binding domain of apoB100 called the B-site and activates platelet p38 MAPK . Activation by B-site peptide is dose-dependent, transient and followed by desensitization, in accordance with receptor-mediated signalling. A scrambled peptide and a partially homologous peptide RKLRKRLLRDA mimicking the apoB/E receptor binding site of apoE in High Density Lipoprotein (HDL) also activate p38 MAPK albeit 40% weaker, but an uncharged peptide lacks p38 MAPK activating capacity. LDL and B-site peptide bind to the same binding sites and initiate similar signaling to p38 MAPK and cytosolic phospholipase A 2 . Thus, LDL and to a lesser extent HDL activate platelets via specific domains in the protein moiety that recognize receptors of the LDL receptor family.
Introduction
The Low Density Lipoprotein (LDL) particle contains one molecule of apolipoprotein B100 (apoB100) that enwraps LDL like a belt, with the carboxyl tail crossing apoB100 close to amino acid 3500 1 . The positively charged amino acids arginine and lysine on apoB100 are essential for recognition of the classical LDL receptor on nucleated cells, the apoB/E receptor [2] [3] [4] . ApoB100 contains several positively charged segments of which residues 3359-3369 are critical for receptor recognition 5 . This domain is called the B-site and consists of the amino acids RLTRKRGLKLA. There is a high similarity with the receptor-binding domain of apoE, present on HDL, which consists of RKLRKRLLRDA 6 . The interaction of the carboxyl tail of apoB100 with residue 3500 allows the B-site to interact with the receptor 7 . This interaction is critical since an R3500Q mutation found in patients with familial defective apoB100 results in loss of receptor binding 8 . Native LDL activates endothelial cells 9 and increases the sensitivity of blood platelets to agonist stimulation [10] [11] [12] [13] [14] . How LDL interacts with platelets is still unclear. Patients with an apoB/E receptor defect have platelets that respond normally to LDL. Antibodies against the apoB/E receptor interfere with LDL binding to lympho-cytes and fibroblasts but leave LDL binding to platelets unaffected. These observations suggest that the LDL receptor on platelets differs from the classical apoB/E receptor present on nucleated cells 15 . A recent study identified LRP8, a member of the LDL receptor family, on platelets and showed that apoE changes platelet functions by binding to this receptor 16 . By analogy, the same or a closely related family member might function in LDL binding to platelets. A first step in platelet activation by LDL is the activation of the enzyme p38 MAPK , which is activated within 10 seconds (at 1 g apoB100/L) after addition of LDL and at concentrations as low as 0.1 g apoB100/L (within 10 minutes) 17 . P38
MAPK is a member of the family of proline directed serine/threonine kinases, which is activated by the simultaneous phosphorylation of Thr 180 and Tyr 182 18 . LDL-induced p38 MAPK activation is insensitive to many inhibitors of signal transduction suggesting that it is an early step in the activation cascade initiated by LDL. An upstream inhibitor of LDLinduced p38 MAPK activation is cAMP. An important downstream effect is the phosphorylation and activation of cytosolic phospholipase A 2 (cPLA 2 ) resulting in formation of thromboxane A 2 and enhanced platelet functions 17 . There is little insight in the activating properties of LDL. LDL consists of free and esterified cholesterol, triglycerides and phospholipids, which are all components that might change cell composition and behaviour. 19 Furthermore, LDL is easily oxidized which leads to the generation of lysophosphatidic acid, which is an inducer of platelet shape change 20 . On the other hand, modification of lysine residues on apoB100 impairs LDL binding to platelets 21 and abolishes LDL induced phosphorylation of p38 MAPK 17 , suggesting that the signaling properties of LDL are located in apoB100.
Here we report that an activating property of LDL resides in the B-site of apoB100. By applying antibodies against apoB100 domains and peptides that mimic the Bsite we find activation of p38 MAPK with characteristics that point to receptor mediated platelet activation. A weaker activation is found by a peptide mimetic for the receptor recognition site of apoE, a constituent of High Density Lipoprotein (HDL) suggesting that the platelet LDL receptor shares many characteristics with the classical apoB/E receptor on other cells.
Materials and Methods
Antibodies and Reagents BAPTA-AM was from Calbiochem Corporation (La Jolla, CA, USA) and SK&F was obtained from Biomol (Sanvertech, Boechout, Belgium). Dibutyryl cyclic AMP (dbcAMP) was from Sigma (St. Louis, MO, USA) and iloprost from Schering (Berlin, FRG). PP1 was obtained from Alexis Biochemicals (San Diego, CA, USA). MoAb directed against cPLA 2 (4-4B-3C) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Renaissance chemiluminescence Western-blot reagent was from NEN-Dupont, Boston, MA, USA. Polyclonal antibodies against p38 MAPK and dual phosphorylated p38 MAPK (phosphoplus p38
MAPK
) and horseradish peroxidase labelled anti-rabbit IgG were from New England Biolabs (Beverly, USA). Non-fat dry milk was obtained from Nutricia (Zoetermeer, the Netherlands). The fibrinogen-derived peptide HHLGGAKQAGDV (γ 400-411 ) was kindly provided by the department of Biochemistry, Utrecht University. SDZ-GPI-562 (GPI-562) was a kind gift of Dr. H-G. Zerwes (Novartis Pharmaceuticals, Basel, Switzerland) 22 . The anti-human apoB100 monoclonal antibodies (moAb) 4G3 and 2D8 were obtained from the University of Ottowa Heart Institute (Ontario, Canada). The production of these antibodies was described before 23 .
Peptides
Peptides were synthesized by standard solid-phase peptide synthesis and purified by C18 reverse-phase chromatography (HPLC, Genosphere biotechnologies, Paris, France). The purity of the peptides was >99% as determined by HPLC and the molecular weights were verified by matrix-assisted laser desorption mass spectrometry by the manufacturer. The peptide RLTRKRGLKLA (Mw = 1311 Da), designated B-site peptide, represents the apoB receptorbinding domain; SLTSASGLALA (Mw = 990 Da) is a related peptide in which charged amino acids have been replaced by uncharged amino acids and was named uncharged peptide. Peptide TKLRALRKLRG is a scrambled peptide with the same composition as B-site peptide. Peptide RKLRKRLLRDA (Mw = 1426 Da) mimics the receptor binding site of apoE and was named apoE peptide.
Lipoprotein Isolation
Lipoproteins were isolated as described previously 10 . In short, fresh, non-frozen plasma from 4 healthy subjects each containing less than 100 mg lipoprotein(a)/L was pooled and LDL (density range 1.019-1.063 kg/L), HDL (density range 1.063-1.21 kg/L), HDL 2 (density range 1.063-1.125 kg/L) and HDL 3 (density range 1.125-1.21 kg/L) were isolated by sequential flotation in a Beckman L-70 ultracentrifuge 24 . Centrifugations (20 hr, 175000 g, 10°C) were carried out in the presence of NaN 3 and EDTA. The LDL preparations contained only minimal amounts TBARS (0.20 ± 0.07 nmol/mg apoB100), lipid peroxides (6.7 ± 1.9 nmol/mg apoB100) and contaminating plasma proteins. The concentrations of these oxidation markers were below or within reported values for native LDL 10 . Lp(a) concentrations (Apotech, Organon Technika, Rockville, U.S.A) were below 14 mg/L.
Lipoproteins were stored at 4°C under nitrogen for not longer than 14 days and before each experiment dialyzed overnight against 10 4 volumes 150 mmol/L NaCl. ApoB100, apoAI and lipoprotein(a) concentrations were measured using the Behring Nephelometer 100. The concentration of LDL was expressed as g apoB100 protein/L and the concentration of HDL as g apoAI protein/L.
Platelet Isolation
Freshly drawn venous blood from healthy volunteers was collected with informed consent into 0.1 vol. 130 mmol/L trisodium citrate. The donors claimed not to have taken any medication during two weeks prior to blood collection. Platelet-rich plasma (PRP) was prepared by centrifugation (200 g for 15 min at 22°C). Gel-filtered platelets (GFP) were isolated as described before 17 . GFP were adjusted to a final count of 2 * 10 11 platelets/L and incubated with peptides, LDL or HDL at 37°C without stirring. I-LDL (60 min, 22°C), and aliquots of 100 µL were layered on top of 100 µL 25 % (w/v) sucrose in Tyrode solution in microsedimentation tubes (Sarstedt, Nümbrecht, Germany). Cells were separated from medium by centrifugation (12000 g, 2 min, 22°C) and both fractions were counted in a Cobra gamma-counter (Packard, Downers Grove, Il., U.S.A.). Aspecific binding (about 10% of total binding) was determined by addition of a 30-fold excess unlabeled LDL and substracted from total binding to obtain specific binding data.
Measurement of p38
MAPK and cPLA 2 The phosphorylation of p38 MAPK and cPLA 2 was measured as described elsewhere 17 . In short, GFP were incubated at 37°C with peptides or LDL as indicated. Samples of 100 µL were fixed in 1% formaldehyde (15 min, 4°C), centrifuged (9000 g, 30 sec) and resuspended in 40 µL Laemmli sample buffer. Samples were heated prior to SDS-polyacrylamide gel electrophoresis (12%). Proteins were electrophoretically transferred (1hour, 100 volts) to a nitrocellulose membrane using a mini-protean system (Biorad, Richmond, CA, USA). The blots were blocked in 5% non-fat dry milk, 0. MAPK was visualized using the enhanced chemiluminescence reaction. For semi-quantitative determination of the amount of dual phosphorylated or total p38 MAPK , the density of the bands was analysed using ImageQuant software (Molecular Dynamics). For the measurement of cPLA 2 phosphorylation, samples were withdrawn and collected in Laemmlli sample buffer (0.001% bromophenol blue, 5% β-mercaptoethanol, 100% glycerol, 2% (w/v) SDS, 62.5 mmol/L Tris pH 6.8). Measurement of cPLA 2 was based on the mobility shift on SDS-PAGE that accompanies phosphorylation of the protein. 27 The running buffer for electrophoresis of cPLA 2 was pH 8.3. cPLA 2 was detected using the moAb 4-4B-3C. Immune complexes were detected by enhanced chemiluminescence.
Statistics
Data are expressed as means ± SD with number of observations n, and were analyzed by ANOVA. Differences were considered significant at P < 0.05.
Results

Identification of the activating domain in apoB100
In an attempt to identify which part in LDL induced platelet activation via p38 MAPK , antibodies were sought that interfere with LDL binding to the classical apoB/E receptor. Anti-human apoB100 monoclonal antibody 4G3 is directed against an amino terminal part of apoB100 close to the apoB receptor-binding site (amino acids 2980-3084) and called B-site. This antibody inhibits LDL-binding to the apoB/ E receptor on human fibroblasts. Antibody 2D8 is directed against a domain distant from the apoB/E receptor-binding site of human fibroblasts (aa 1438-1481) and does not interfere with LDL binding 5, 23 . As illustrated in Figure 1 , 4G3 induced a dose-dependent decrease in p38 MAPK phosphorylation by LDL. In contrast, phosphorylation of p38
MAPK was unchanged when LDL was pretreated with 2D8, suggesting that the domain recognized by this antibody was not involved in p38 MAPK activation by LDL. Hence, despite the differences between the classical apoB/E receptor and the platelet LDL-receptor, both receptors appeared to be recognized by the B-site in apoB100.
B-site peptide activates platelet p38 MAPK
To better understand the role of the B-site in LDL activation of platelets, a mimicking peptide was synthesized together with peptides with the same amino acid composition in random order (scrambled peptide) and a peptide in which charged amino acids were replaced by uncharged amino acids (uncharged peptide). Samples were subjected to SDS-PAGE and identified with an antibody directed against phosphorylated p38 MAPK . Figure 2A depicts the time-dependent phosphorylation of p38 MAPK induced by B-site peptide. Within 30 seconds a strong increase in p38 MAPK phosphorylation was observed, reaching a maximum between 0.5 and 2 minutes, depending on the donor. P38
MAPK phosphorylation induced by B-site peptide was transient and disappeared within 15 minutes. MAPK was identified and the data were expressed as percentage of the p38 MAPK phosphorylation observed after incubation with 1 min B-site peptide. Data are expressed as means ± SD, n=4. (E), Platelets were incubated with B-site peptide or uncharged peptide (100 µmol/L, 37°C) for the indicated time periods. Dual phosphorylated p38 MAPK was identified as described in Figure 2A . Shown is a representative blot of three experiments with identical results.
In the lower panel the same samples were analysed with an antibody directed against total p38 MAPK , showing that similar amounts of p38 MAPK were present in all samples. An optimal effect was observed at 100 µmol/L B-site peptide ( Figure 2B ). At this concentration B-site peptide induced 93.6 ± 4.1% (n=5, P>0.5) of the p38 MAPK phosphorylation induced by 1 g/L LDL. However, activation by the peptide lasted shorter than activation by LDL, indicating that B-site peptide mimicked only part of the activating properties of native LDL ( Figure 2C ). The scrambled B-site peptide had retained part of the activating properties of intact B-site peptide ( Figure 2D ). There was a slight and transient activation which reached about 60% of the increase in phosphorylated p38
MAPK triggered by intact B-site peptide. This indicates that part of the activating properties of B-site peptide are caused by positively charged amino acids. Indeed, when all charged amino acids were replaced by neutral amino acids by means of arginine-serine and lysine-alanine replacements, the activating properties were lost ( Figure 2E ). Together these data illustrate that B-site peptide is a rapid and strong activator of p38 MAPK in platelets.
Comparison between B-site peptide and LDL
The observation that B-site peptide mimicked at least part of the p38 MAPK activating properties of LDL suggested that both induced signal generation by binding to a single class of LDL receptors. To substantiate this conclusion, platelets were incubated for 60 minutes with 30 mg/L 125 I-labeled LDL (22°C) to reach equilibrium binding to LDL binding sites on the platelet surface. Prior addition of B-site peptide (10-160 µmol/L) led to a dose-related displacement of bound 125 I-labeled LDL ( Figure 3A ). This accords with competition for a single class of binding sites. A common property of most receptors is that they become unresponsive after prolonged ligand occupation. Indeed, a 30 minutes incubation with B-site peptide led to downregulation of p38 MAPK activation (Figures 2C and 3B) . A second addition of 100µmol/L B-site peptide failed to trigger a second p38 MAPK phosphorylation response, suggesting that the B-site recognition mechanism had become desensitized. Together these findings support the concept that LDL and Bsite peptide bind to the same receptors thereby starting signal transduction to p38 MAPK .
To further compare the signaling properties of B-site peptide and LDL, the sensitivity of p38 MAPK phosphorylation for agents that interfere with platelet activating pathways was investigated. We have shown earlier that LDL-induced p38 MAPK was inhibited by agents that raise cAMP whereas the Ca 2+ -scavenger BAPTA-AM and the Ca 2+ -entry blocker SK&F had no effect 17 . B-site induced p38 MAPK phosphorylation showed the same characteristics. There was a strong inhibition by the stable PGI 2 -analogue iloprost and the cell-permeable cAMP analogue dibutyryl cAMP but no effect of treatment with BAPTA-AM and SK&F ( Figure 4A ). Another feature of LDL-induced p38 MAPK phosphorylation is lack of involvement of integrin αIIbβ3. B-site peptide-induced p38 MAPK activation also showed no requirement of integrin αIIbβ3 as blockers of ligand binding to the integrin, fibrinogen γ-chain derived dodecapeptide (γ 400-411 ) and GPI-562 showed no effect ( Figure 4B ). The role of Src family tyrosine kinases in B-site and LDL-induced p38
MAPK activation was investigated with the specific inhibitor PP1. At two concentrations (10 µmol/L and 20 µmol/L) the inhibitor markedly reduced B-site and LDL-induced p38 MAPK phosphorylation, illustrating the involvement of Src family tyrosine kinases ( Figure  4C ).
One of the downstream effects of LDL-induced p38
MAPK phosphorylation is the phosphorylation of cPLA 2 , which is a first step in the generation of thromboxane A 2 . Also B-site peptide (100 µmol/L) induced a transient phosphorylation of cPLA 2 but the effect was considerably faster than observed with LDL 27 such in accordance with the faster phosphorylation of p38 MAPK induced by the peptide ( Figure 5) . B-site peptide phosphorylation of cPLA 2 was blocked completely by the p38 MAPK inhibitor SB203580 confirming the role of p38 MAPK in the control of cPLA 2 . These data indicate that B-site peptide initiates the same type of signal transduction in platelets as LDL.
P38
MAPK phosphorylation by the receptor-binding site of apoE The apoB/E receptor equally recognizes the apoB-100 part of LDL as the apoE part of HDL and a high degree of similarity between the receptor recognition domains of both apolipoproteins can be expected. Indeed, also HDL induced p38 MAPK phosphorylation but the response was weaker than observed with LDL ( Figure 6A ). Subtypes of HDL, HDL 2 and HDL 3 , which are described respectively as antiaggregatory and proaggregatory 28 induce p38 MAPK phosphorylation with HDL 2 acting as a weaker agonist ( Figure 6B ). Residues 142-152 of apoE show a high degree of homology with the B-site of apoB100. A peptide mimicking this domain called apoE peptide (RKLRKRLLRDA) also induced phosphorylation of p38 MAPK ( Figure 6C ). The phosphorylation was fast and transient and also accompanied by loss of responsiveness to a second addition of apoE peptide. These properties closely resemble those observed with B-site peptide.
Discussion
This report shows that at least part of the platelet activating properties of LDL are located in apoB100. This agrees with earlier studies in which carbamylation of apoB100 abolished LDL-induced p38 MAPK phosphorylation reflecting a crucial role of the protein moiety in platelet activation by LDL 17 . Antibodies against different domains of apoB100 reveal a central role for the B-site in induction of p38 MAPK phosphorylation. This domain is crucial for LDL binding to the apoB/E receptor on fibroblasts and apparently also functions in LDL binding to the LDL receptor on platelets. This is of interest since observations in patients with an apoB/E receptor defect as well as in vitro studies with antibodies indicate that platelets lack the classical apoB/E receptor. Possibly, platelets contain a closely related LDL receptor family member with some properties in common with the apoB/E receptor. Earlier studies by Borén et al suggested that the B-site of apoB100 (residues 3359-3369) was critical site for LDL binding to the apoB/E receptor 29 . In contrast, Law and Scott proposed that multiple sites on apoB100 mediated receptor-binding 30 with the B-site playing a dominant but not an exclusive role. The present study shows that a B-site mimicking peptide induces signal transduction in platelets. Phosphorylation of p38 MAPK was observed within 30 seconds after addition of B-site peptide, illustrating rapid binding and activation of platelets. The activation was maximal at about 100 µmol B-site peptide/L, which is equivalent to 0.13 g protein/ L. At this concentration B-site peptide induced the same amount of p38 MAPK phosphorylation as 1.0 g LDL protein/L, suggesting that the B-site contains a major part of the platelet activating properties of LDL. P38
MAPK phosphorylation induced by the peptide was faster and more transient than induced by LDL. The difference might be caused by different binding affinities of the peptide and LDL. Alternatively, the B-site might be important for platelet-LDL receptor recognition and initial signal transduction generation with other components in LDL supporting this process at later stages of LDL-platelet contact. A B-site peptide with arginine-serine and lysinealanine replacements failed to induce p38 MAPK activation. A scrambled B-site peptide has preserved part of the activating properties. This illustrates the importance of clusters of positively charged amino acids lysine and arginine for platelet activation by apoB100, such in common which apoB100 binding to the apoB/E receptor 2, 3 . Also LDL binding to proteoglycans is charge-dependent 31 . A minimum of five positive charges with intervening nonbasic amino acids in a nonapeptide was required for the binding to proteoglycans 32 . Binding affinity depended on number and type of nonbasic amino acids. In this respect, the B-site and the apoE site investigated in the present study bind much stronger to proteoglycans than other charged domains in these apolipoproteins. The possibility to displace platelet-bound LDL by B-site peptide and the loss of responsiveness after prolonged incubation with B-site peptide suggests the involvement of a surface receptor that mediates signals to p38 MAPK . The desensitization might be the result of endocytosis of receptor-ligand complexes as has been reported for ligand occupied apoB/E receptors on fibroblasts 33 . However, in studies by Pedreno et al 125 I-LDL binding was reversible and unaffected by changes in temperature which would argue against receptor internalization 15, 34 . In contrast, Mazurov et al reported a temperature dependent decrease of fluorescent-LDL bound to platelets and concluded that bound LDL was internalized 35 . B-site peptide and LDL appear to trigger the same signaling pathway to p38 MAPK .
P38
MAPK phosphorylation by both agonists was inhibited by cAMP, independent of Ca 2+ increases and abolished by PP1, an inhibitor of Src family tyrosine kinases. In addition, both agonists induced phosphorylation of cPLA 2 , which is a key step in enzyme activation leading to formation of thromboxane A 2 . Although B-site peptide and LDL induced the same degree of p38 MAPK activation during initial contact with the platelet, the peptide failed to sensitize collagen-induced secretion of dense granule contents, such in contrast to LDL (data not shown). Thus, the more prolonged activation observed with LDL might initiate a stronger stimulation of the cPLA 2 pathway leading to more support of platelet functions 12, 14, 28, [36] [37] [38] . Since the B-site of apoB100 shows a high degree of homology with the receptorbinding domain of apoE 39 , one might expect a similar activation by a peptide that mimics this part of apoE. Indeed, apoE peptide induced a similar p38 MAPK phosphorylation as B-site peptide but the activation was much weaker. A 30 minutes incubation followed by a second peptide addition revealed a similar desensitization as observed with B-site peptide. These findings are in concert with the rapid down-regulation of binding sites for radiolabeled HDL 3 on platelets as well as desensitization of the signaling pathway 40, 41 . In this respect apoE peptide mimicked the effect of HDL which was a weaker activator than LDL when concentrations were based on apoA-I and apoB100 content respectively. Applying molar concentrations and an apoA-I/ apoE ratio of about 30, the same concentration range resulted in a 2-3 fold lower HDL-apoE concentration compared with LDL-apoB100. Also on this basis, HDL was a weaker activator of p38 MAPK than LDL. HDL 3 induced a stronger p38 MAPK activation compared to HDL 2 in concert with the pro-aggregatory effect of HDL 3 on platelets 28 . However, HDL 2 is the apoE-rich fraction of HDL whereas HDL 3 is the apoE-poor fraction which argues against an unique role of apoE for p38 MAPK activation. The observations suggest that in HDL-induced p38
MAPK phosphorylation in addition to apoE other lipoprotein-related components contribute to platelet sensitization. Although previous observations suggest that the platelet LDL receptor is different from the classical apoB/E receptor, the present data reveal many similarities. Both receptors recognize apoB100 and apoE and the crucial binding domains are the same. Furthermore, positively charged amino acids are essential for receptor binding. These characteristics make it likely that platelets contain a member of the LDL receptor family. A recent study shows that platelets contain LDL receptorrelated protein 8 (formerly termed apoER2). So far, LRP8 has been exclusively demonstrated in human brain and placenta and its presence in platelets is unexpected 42 . Binding of apoE to this receptor inhibited platelet aggregation which is in sharp contrast to the activating effect of apoE peptide on p38 MAPK phosphorylation 16 . The cytoplasmic tail of LRP8 contains several motifs with potential for cellular signaling. Unfortunately, it is not known whether the extracellular part contains an apoB100 binding site which would make it a candidate receptor for the effects presented in the present study.
In conclusion, the results of this study indicate that LDL -and to a lesser extent HDL-induce platelet activation via specific domains in the protein moiety. The receptors that bind these domains share many properties with classical apoB/E receptors which may become desensitized after prolonged contact with these lipoproteins. This might reflect an important protection mechanism by which circulating platelets remain dormant despite the continuous contact with LDL and HDL.
